clarithromycin + clofazimine + infliximab + rifabutin

This is a combination regimen consisting of four drugs—clarithromycin, clofazimine, infliximab, and rifabutin. Each component has a distinct mechanism of action:

• Clarithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.
• Clofazimine is an antimycobacterial agent with anti-inflammatory properties; it binds to mycobacterial DNA and disrupts replication and transcription.
• Infliximab is a chimeric monoclonal antibody that targets tumor necrosis factor alpha (TNFα), inhibiting its pro-inflammatory activity.
• Rifabutin is an antibiotic in the rifamycin class that inhibits DNA-dependent RNA polymerase in bacteria, suppressing RNA synthesis and leading to cell death.

This combination may be considered for complex infections involving mycobacteria or for investigational use in severe inflammatory or infectious diseases where both immunomodulation (via infliximab) and broad-spectrum antimycobacterial coverage are required.